AzTrials
AzTrials

DepressionPhase 3NCT00720200

ICU Family Communication Study

A Phase 3 study testing Facilitator-Based intervention in people with Depression and Depressive Symptoms, run by University of Washington at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to improve care in the Intensive Care Unit (ICU) by focusing on communication with family members of patients who are too sick to make decisions about their own care while they are in the ICU. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Depression, Depressive Symptoms, Anxiety
What is being tested?
Facilitator-Based intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
593 participants
Where
2 sitesUnited States
Study dates
Jun 2008to May 2014
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients, family members, clinicians attending ICU family conferences, and nurses evaluating the quality of care.
  • All ICU patients are eligible if they meet the age criteria, have been in the ICU for at least 12 hours, have acute respiratory failure requiring mechanical ventilation at the time of enrollment, and have an APACHE II score/SOFA score or other diagnosis that predicts a 30-50% or greater risk of mortality.
  • Eligible family members and/or friends may include any of the following: legal guardians, durable power of attorney for healthcare, spouses, adult children, parents, siblings, domestic partners, other relatives, and friends; if they meet the age criteria, and understand English well enough to complete informed consent and study materials.
  • Eligible clinicians include those who are present during a family conference and may include physicians, nurses, nurse practitioners, physician assistants, social workers, respiratory therapists, and clergy.
  • All critical care nurses are eligible to participate in the evaluation if they have provided care to a patient on or before the shift in which he or she died or was discharged from the ICU.

Who cannot join

  • Legal or risk management concerns (as determined by the attending physician or via hospital record designation);
  • Psychological illness or morbidity; and
  • Physical or mental limitations preventing ability to complete questionnaires.
  • Patients will be excluded if they do not have at least one family member who is eligible and willing to participate in the study.
  • A patient who is readmitted to the ICU, if the patient was enrolled and discharged previously, will not be eligible.
  • Post-operative patients who have been admitted to the ICU after a scheduled surgery without complications will be excluded. These patients may meet other eligibility criteria (ventilation, APACHE scores, etc.) within the first 12 to 48 hours of admission, but will usually improve quite rapidly after that period.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Valley Medical Center

    Renton, Washington, 98058

  • Harborview Medical Center

    Seattle, Washington, 98104

Other trials in United States

About this study

Official title: A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit

The purpose of this study is to improve care in the Intensive Care Unit (ICU) by focusing on communication with family members of patients who are too sick to make decisions about their own care while they are in the ICU. The randomized trial will test the efficacy of a communication intervention designed to improve communication between families and clinicians through the use of a facilitator. Outcome evaluation occurs at the level of the individual family with surveys completed by families and clinicians.

Read the detailed description

Three decades of research on end-of-life care in the United States indicate that people who are dying often spend their final days receiving care they would not choose. The intensive care unit (ICU) is an important focus for efforts to improve end-of-life care both because death is common in this setting - approximately 20% of Americans die in or shortly after a stay in the ICU - and also because care is highly technologic and, thus, expensive. As a result of our prior work we have developed a wealth of knowledge about how to improve communication and decision-making concerning end-of-life care in the ICU. One of the important insights from this knowledge was the need for and development of a facilitator-assisted interdisciplinary communication intervention. This intervention, designed to improve communication and decision-making about end-of-life care in the ICU, offers significant potential benefits for improving patient- and family-centered care for five reasons: 1) communication is an integral component of clinician skill that affects all other aspects of end-of-life care; 2) physicians and nurses in practice do not demonstrate adequate skills for communicating about end-of-life care, especially in the ICU or acute care setting; 3) interventions that have focused on improving communication within the ICU team and between the team and the family have been shown to reduce the "prolongation of dying" common in the ICU, but it remains unclear how to generalize these successes to other hospitals; 4) a recent randomized trial in France used an intervention based on our prior research and showed dramatic reductions in symptoms of anxiety, depression, and post-traumatic stress disorder (PTSD) among family members after the patient's death, but it is unclear how to translate these findings to hospitals in the U.S.; and 5) sustainable, generalizable, and widely available interventions that improve communication about end-of-life care are not available.

The long-term objectives are: 1) to demonstrate the efficacy of a generalizable facilitator-assisted interdisciplinary communication intervention in the ICU to improve family and patient outcomes; and 2) to demonstrate the feasibility of making this intervention a routine part of clinical practice in the ICU setting.

The study will advance Nursing science by addressing an important area of emphasis within Nursing science and a key component of the National Institute of Nursing Research's strategic plan. One fifth of deaths in America occur in intensive care units and nurses provide a key component of the care in this setting. With the aging population and coincident advances in medical technology, more patients are likely to die after an unsuccessful trial of intensive care. Prior research suggests that interventions to improve communication about end-of-life care in the ICU may reduce the prolongation of dying that is common in the ICU setting while at the same time improving the quality of care for patients and family members. Unfortunately, this prior research does not provide a clear generalizable intervention that can be easily implemented in academic and community hospitals. The proposed randomized trial will test a feasible and generalizable intervention to improve communication about end-of-life care and improve patient and family outcomes.

The consent forms used for this study address the purpose, procedures, risks, alternatives, benefits, and other information -- including emphasis on the voluntary nature of this research and assurances of confidentiality.

The conceptual model for the intervention addresses three components of self-efficacy theory: 1) knowledge, based on this team's prior research identifying components of communication during ICU family conferences that are associated with improved patient and family outcomes; 2) attitudes, informed by attachment theory as applied to clinician-patient relationships and communication; and 3) communication behaviors informed by principles of mediation based on identifying and resolving conflict in the healthcare setting.

The intervention includes the following steps: 1) in-person interviews by the facilitator with the family prior to the family conference in order to discuss the family's concerns, questions, needs and unique communication characteristics that will be addressed in the family conference; 2) a pre-conference meeting with the facilitator, physician(s), nurse(s), and other clinicians in which a brief summary describing the family's concerns, questions, needs, and unique communication characteristics is presented and discussed; 3) facilitator participation in the family conference; and 4) facilitator follow up with the family throughout the ICU stay. Prior to the facilitator's involvement, both the intervention and control group will meet with the research coordinator who will obtain consent from the family and distribute baseline questionnaires; the research coordinator will also contact both the intervention and control group families at the time of the follow-up questionnaires (3 and 6 months after discharge or death) to notify them that questionnaires are being sent to them and ask if they have any questions. The contacts through the research coordinator are expected to enhance response rates for both groups. For the control group, these contacts with the research coordinator will provide an "attention control." The research coordinator will not provide any of the other intervention components provided by the facilitator (i.e., discussion of concerns or questions prior to the family conference; brief summary to clinicians; participation in the family conference; follow-up contact after the family conference for duration of the ICU stay). A component of the facilitator's role will also include helping to identify the need for a family conference and scheduling these conferences. Therefore, as part of the multi-faceted intervention, we anticipate that family conferences will occur earlier and more frequently in the intervention arm. After the initial family conference, there may be additional family conferences and the facilitator will participate in these conferences for the intervention group.

Being tested
Facilitator-Based intervention, Usual Care
Keywords
Communication, Intensive Care Units, Palliative Care, End-of-Life Issues, Talking with Your Doctor, Coping with Chronic Illness
Medical subject headings
Depression, Anxiety Disorders, Stress Disorders, Post-Traumatic, Communication

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Facilitator-Based interventionBehavioural

    Family Members receiving facilitator-based intervention

  • Usual CareBehavioural

    Family Members receiving usual care/clinical interaction

Study groups in NCT00720200
Study groupRoleWhat they receive
1ExperimentalNot described
Receives: Behavioral: Facilitator-Based intervention
2Active comparatorNot described
Receives: Behavioral: Usual Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patient Health Questionaire (PHQ-9)

    Family symptoms of depression after the patient dies or is discharged from ICU as assessed by a survey

    Measured: At 3- and 6- months following the death of the patient

Secondary outcomes (8)
  1. Post-Traumatic Stress Disorder Checklist (PCL)

    Symptoms of PTSD

    Measured: At 3- and 6- months following the death of the patient

  2. Generalized Anxiety Disorder (GAD-7) Survey

    Anxiety

    Measured: At 3- and 6- months following the death of the patient

  3. Quality of Dying and Death Questionaire

    Measured: Following death of patient

  4. Evaluate length of stay in ICU/hospital

    Measured: During hospital stay

  5. Costs during ICU stay including estimated costs of intervention

    Measured: During ICU length of stay

  6. Families' ratings of the quality of communication generally and specifically in the family conference

    Measured: During ICU length of stay

  7. Clinicians' ratings of the quality of clinician-family in the family conference

    Measured: During ICU length of stay

  8. Clinicians' ratings of nurse-physician collaboration

    Measured: During ICU length of stay

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2008 (estimated)
  2. Study startJun 2008
  3. Primary completionMar 2014
  4. Study completionMay 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
593 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00720200
Sponsor's protocol ID
33584-C
Other IDs
2R01NR005226
Status last verified
Sep 2014
First submitted
18 Jul 2008
Last updated
16 Sep 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Curtis JR, Ciechanowski PS, Downey L, Gold J, Nielsen EL, Shannon SE, Treece PD, Young JP, Engelberg RA. Development and evaluation of an interprofessional communication intervention to improve family outcomes in the ICU. Contemp Clin Trials. 2012 Nov;33(6):1245-54. doi: 10.1016/j.cct.2012.06.010. Epub 2012 Jul 6.

    PubMed 22772089
  • Curtis JR, Treece PD, Nielsen EL, Gold J, Ciechanowski PS, Shannon SE, Khandelwal N, Young JP, Engelberg RA. Randomized Trial of Communication Facilitators to Reduce Family Distress and Intensity of End-of-Life Care. Am J Respir Crit Care Med. 2016 Jan 15;193(2):154-62. doi: 10.1164/rccm.201505-0900OC.

    PubMed 26378963

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Facilitator-Based intervention in people with Depression and Depressive Symptoms, run by University of Washington at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patient Health Questionaire (PHQ-9) (time frame: At 3- and 6- months following the death of the patient). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00720200, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2014.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in